The effect of thiamin tetrahydrofurfuryl disulfide on behavior of juvenile DBA/2J mice hypothesized functions include regulation of enzyme expression (e.g.,
60
( Pekovich et al., 1998a) ); alteration of neuronal membrane ion channels 61 that result in prolonged depolarization responses (Houzen and Kanno, 62 1998; Tallaksen and Tauboll, 2000) ; maintenance of nerve membrane 63 potentials (Itokawa, 1996) ; alteration of neurotransmitter release 64 (Yamashita et al., 1993) or uptake (Thomson and Marshall, 2006) ;
The timeline for the behavioral study is given in Table 1 . 
Growth and organ weights 176
Experimental mice were weighed daily before gavage, and body 177 length (nose to rump) was determined at the start of the study and 178 before necropsy. Mice were observed at both the start and end of the 179 study to detect any changes in general activity, ambulation, posture, Weigh, measure length, observe, necropsy for organ weights a n = 24 T0 (control), 23 T100 (100 mg TTFD/kg body weight), 24 T340 (340 mg TTFD/kg body weight) t1:15
appearance, or behavior. On PND 34, 3 h after gavage, mice were 181 euthanized by CO 2 inhalation, and the brain, testes, liver, spleen, 182 kidneys, and heart were rapidly removed and weighed. animal filters out extraneous information and protects against sensory 234 overload for (review see (Swerdlow et al., 2008) Swerdlow et al., 2008) . In rodents the startle response itself is commonly 240 used to assess emotional reactivity and the effects of anti-anxiety drugs 241 (Bourin et al., 2007; Grillon, 2008; McCaughran et al., 2000) . Species and 242 strains within species differ in their regulation of startle and PPI 243 (Swerdlow et al., 2008) .
244
A commercial startle reflex system (SR-LAB, San Diego Instru-245 ments, San Diego, CA), previously described (Berman et al., 2008) 
283
The results of analyses showing significance of TTFD effects are compared to T0 percent weight change of both T100 and T340 mice 347 was lower (Fig. 1A) , but growth in length did not differ between 348 treatment groups (Fig. 1B) Table 3) . Changes in weight and length (nose to rump) between study start and study finish were computed for each mouse. (A) ANCOVA for PctWtChg showed T0 N T100 and T340, P b 0.05 each. (B) ANCOVA for PctLnChg showed no between-group differences. Between-group differences are indicated by a vs. b notation. Error bars represent S.E.M. T0 = control (n = 19), T100 = 100 mg TTFD/kg body weight (n = 20), T340 = 340 mg TTFD/kg body weight (n = 23).
Activity monitoring

375
During the first 30 min (adaptation) of the monitoring period,
376
TTFD-treated mice differed from control on three activity variables 377 (Table 5 , Fig. 3 ). Compared to T0, percent time in the arena center was 378 reduced in both the T100 and T340 mice (Fig. 3B) ; localized repetitive 379 movement was significantly reduced for T340 mice (Fig. 3C) ; and 380 resting time was increased for both T100 and T340 mice (Fig. 3D ).
381
Treatment did not significantly affect horizontal locomotor activity 382 (Fig. 3A) . Habituation to the testing environment is indicated by 383 significant time (3-min sample) effects for each behavior. Greater 384 percent weight change (PctWtChg) was overall associated with 385 greater horizontal locomotor activity.
386
For the remainder of the 24-h period that was synchronized for the 387 light/dark cycle (Table 5 , Fig. 4 ), significant treatment effects occurred WtCur = current weight, ASPPI test = test for prepulse inhibition of acoustic startle, PctWtChg = percent change in weight from study start to necropsy, PctLnChg = percent change in body length from study start to necropsy, Tx = treatment, WtSt = body weight at study start (PND 18), LnSt = body length (nose to rump) at study start (PND 18), rPctWtChg = residual from regression of percent weight change on treatment.
t3:10 a n = 19 T0, 20 T100, 23 T340 t3:11 b Vertical bars (|) indicate that significance of all indicated effects and their interactions was tested; however, as noted, the F test and significance levels are only listed for treatment (whether or not it reached significance) and other effects and interactions that reached significance. t3:12 Fig. 2 . Duration of activity in four behavior categories during social dyadic interaction (Table 4) . Behaviors were quantified in two 10-min sessions for each mouse, and means of the two sessions are shown in the figure. ANCOVA of session means showed TTFD-treated groups differed from controls in three behavior categories: Social Passive, T340N T0 (P= 0.01); Social Active, T0N T100 and T340 (P b 0.005 and 0.01, respectively); and Total Active T0N T100 and T340 (P b 0.0005 each). Between-group differences are indicated by a vs. b notation. Error bars represent S.E.M. T0= control (n= 19), T100 = 100 mg TTFD/kg body weight (n= 20), T340 = 340 mg TTFD/kg body weight (n= 23). Analyses were conducted on behavior categories using (1) repeated measures on 2 test sessions and (2) the means of the 2 sessions.
t4:14 Tx = treatment. t4:15 a n = 19 T0, 20 T100, 23 T340 t4:16 b Vertical bars (|) indicate that significance of all indicated effects and their interactions was tested; however, as noted, the F test and significance levels are only listed for treatment (whether or not it reached significance). Other effects and interactions did not reach significance. t4:17 t5:26 a n = 20 T0, 21 T100, 22 T340 t5:27 b Vertical bars (|) indicate that significance of all indicated effects and their interactions was tested; however, as noted, the F test and significance levels are only listed for treatment (whether or not it reached significance) and other effects and interactions that reached significance.
t5:28 c Repeated measures analyses were conducted on behaviors during (1) the 30-min adaptation period and (2) the remainder of the 24-h period that was synchronized for onset of the dark cycle.
t5:29
for mean horizontal locomotor activity (Fig. 4A) , with T0 greater than 389 T100; for percent time in the arena center (Fig. 4B) , with T100 greater 390 than T0 at covariate means; for mean localized repetitive movement
391
( Fig. 4C) , with T0 greater than T100; and resting time ( (Table  Q2 6).
400
During the day→night transition period (Fig. 5A-D weight gain observed in these animals.
455
The dosages of TTFD used in this study were selected based on 456 previously published studies with lipophilic thiamin derivatives in 457 mice. However, one of those studies (Micheau et al., 1985) (Lonsdale, 1987a (Lonsdale, , 2006 (Lonsdale, , 2001 (Lonsdale, , 2004 Lonsdale et 465 al., 1982 Lonsdale et 465 al., , 2002 used doses lower than those used in the present study.
466
Attention to the route of administration or to buffering agents may be 467 needed in human studies.
468
Treatment resulted in a lower current body weight in both T100 the stimulus mouse, but the nature of their social interaction differed.
477
Compared to control, TTFD-treated mice showed more passive
478
(cuddling-type) interaction and less boisterous interaction with the (Table 6 ). The arrow indicates placement of mice into the chambers, which was immediately followed by the 30-min adaptation period presented in MBR = mean baseline (no stimulus) response, MSR = mean startle response to pulse alone, dB = decibels of sound, ASPPI = acoustic startle prepulse inhibition, Tx = treatment, rWtCur = residual from regression of current weight on treatment, rMBR = residual from regression of mean baseline response on treatment | rWtCur, * = interaction between effects.
t6:12 a n = 23 T0, 24 T100, 23 T340 t6:13 b Vertical bars (|) indicate that significance of all indicated effects and their interactions was tested (however, as noted, the F test and significance levels are only listed for treatment (whether or not it reached significance) and other effects and interactions that reached significance. to high-dose thiamin (Brenner, 1982) . Improved behavior has also 492 been reported in autistic children treated with TTFD, but the nature of 493 the improvements was not described (Lonsdale et al., 2002) . were coordination problems that may not have been detected in the 520 current testing regimen (Curzon et al., 2009 ).
521
The 24-h data again indicate overall lower activity in TTFD-treated 522 mice compared to control, but in different components. Here control 523 mice showed greater horizontal activity than T100 mice (vs. no 524 between-group differences during adaptation); control mice showed 525 greater localized repetitive movement than only T100 (vs. T0 greater 526 than T340 during adaptation); and the average resting time for 527 controls was less than that of the T100 group (vs. T0 less than both 528 T100 and T340 during adaptation). Percent time in the arena center 529 was increased for T100 mice compared to controls (indicating 530 adaptation to that area with longer exposure), a result contrasting 531 to that found in the adaptation period where time in center was 532 greater for controls than for the T100 and T340 groups. Thus, the 533 dosage of TTFD resulted in differing effects on activity during each 534 activity period (adaptation and 24-h), and effects were not always 535 dose related.
536
The mechanism(s) underlying TTFD's effects on activity are function by TTFD could underlie its effect on brain function (Lonsdale, 541 1987a (Lonsdale, 541 , 1987b (Lonsdale, 541 , 1982a Micheau et al., 1985; Mimori et al., 1996) . In 542 normal human volunteers high-dose thiamin has been reported to 543 counteract hippocampal behavioral deficits induced by the non-544 selective mAChR antagonist scopolamine (Meador et al., 1993) . A 545 number of behavioral deficits seen in thiamin-deficient rodents are Polynomial mixed model analysis (explained in Section 2.7) indicated a significant treatment effect for each activity shown, with treatment × 3-min sample significant (P ≤ 0.05) at one or more levels of interaction in each case (data not shown). Active behaviors were decreased in amplitude for both T100 and T340, and were delayed in the T100 group. T0 = control (n = 20), T100 = 100 mg TTFD/kg body weight (n = 21), T340 = 340 mg TTFD/kg body weight (n = 22).
remediated by pro-cholinergic agents (Nakagawasai et al., 2001 (Nakagawasai et al., , 2000 (Nakagawasai et al., , 547 2007 (Nakagawasai et al., , 2004 . Thiamin can affect acetylcholine levels by (1) increasing 548 levels of acetylcholine precursors via its cofactor roles in the pyruvate 549 dehydrogenase complex (acetyl Co-A production) and transketolase 550 (NADPH/antioxidant protective effect) (Gibson and Blass, 2007; 551 Gloire et al., 2006; Jones, 2000; McGrane, 2000; Salminen and 552 Kaarniranta, 2010; Sheline and Wei, 2006) and increasing the rate 553 of neuronal high affinity uptake of choline (Micheau et al., 1985) , and (Table 7) . Behavior means for each mouse were computed for each measurement and used for ANCOVA. The figures represent treatment group means derived from individual means. Significant treatment effects occurred for (A) mean baseline (no stimulus) response (MBR) with only background noise in the acoustic startle apparatus (T0 b T100 and T340, P b 0.05 and P b 0.0005, respectively); (B) mean startle response to pulse alone (MSR) (T100 b T0, P b 0.05); and (C) startle inhibition by the 82-dB prepulse (ASPPI) (T100 b T0 and T340, P b 0.01 each). For the 74-dB and 90-dB prepulses, no significant treatment effect occurred. Between-group differences are indicated by a vs. b notation. Error bars represent S.E.M. T0 = control (n= 23), T100 = 100 mg TTFD/kg body weight (n= 23), T340 = 340 mg TTFD/kg body weight (n = 23). t7:5 ranked ThMP Tx F 2,13 = 0.48, P = 0.6317 t7:6 1/cubed ThDP Tx F 2,10 = 0.85, P = 0.1383 ThMP = thiamin monophosphate, ThDP = thiamin diphosphate t7:7 a n = 5 T0, 5 T100, 6 T340 t7:8 Fig. 7 . Effect of treatment on the thiamin and thiamin phosphate content of whole mouse brain (Table 8) . Tissue analysis showed between-group differences in the level of thiamin (Thi) (T0 b T100, P b 0.01; T0 b T340, P b 0.001), but no between-group differences in levels of thiamin monophosphate (ThMP) or thiamin diphosphate (ThDP). Levels of thiamin triphosphate (ThTP) and adenosine thiamin triphosphate (AThTP) were too low to quantify accurately. Between-group differences are indicated by a vs. b notation. Error bars represent S.E.M. T0 = control (n = 5), T100 = 100 mg TTFD/kg body weight (n = 23), T340 = 340 mg TTFD/kg body weight (n = 6).
Thiamin-related cholinergic enhancement may also be involved in 563 regulation of circadian rhythm for reviews see (Datta, 2010; 564 Rosenwasser, 2009; Turner et al., 2010) , which could explain 565 differences observed here during the light/dark transition. Subclinical 566 dietary thiamin deficiency altered circadian rhythm in 6 week-old 567 C57BL/6J mice (Bennett and Schwartz, 1999) . Studies using other , 1999) . Our test protocol used broad-band noise in 32-d old mice.
582
Our ASPPI study yielded 4 main findings regarding TTFD effects:
583
(1) TTFD produced a dose-related increase in mean baseline response
584
(the no stimulus response during only broad-band background 585 noise); (2) the response to the startle pulse alone was lower for 586 T100 compared to T0 mice; (3) prepulse inhibition with the 82 dB 587 prepulse was reduced for T100 compared to both T0 and T340 mice; 588 and (4) when mice were matched for startle response, no change in 589 82-dB prepulse inhibition was observed. transketolase, an enzyme for which thiamin diphosphate is a cofactor 616 (Peskin et al., 1967) . Increased startle response was attributed to 617 neurological hyperexcitability and was thought to correlate with 618 reported observations of increased spontaneous activity in preclinically 619 thiamin-deficient rats. We know of no previous reports of supranormal 620 thiamin intake decreasing auditory startle or startle due to other sensory 621 input, however. In rodents the startle response is commonly used to 622 assess emotional reactivity and the effects of anti-anxiety drugs (Bourin 623 et al., 2007; Grillon, 2008; McCaughran et al., 2000 
641
Two recent studies, one in rats (Nozaki et al., 2009 ) and the other 642 in mice (Pan et al., 2010) , also showed elevated levels of thiamin, but (e.g., (Matsui et al., 1985) ), toxicity due to heavy metals and various 662 chemicals (Fujiwara, 1965; Lonsdale et al., 2002; Reddy et al., 2010) , 663 alcoholic and nutritional polyneuropathies and myopathies (Djoenaidi et 664 al., 1992; Woelk et al., 1998) , dysautonomic symptoms (Lonsdale, 2009), 665 infant brainstem dysfunction and apnea (Lonsdale, 2001) , postinfectious 666 asthenia (Shah, 2003) , psychobehavioral inhibition occurring during 667 major depression (Loo et al., 2000) , and various disorders possibly 668 associated with thiamin dependency that are expressed particularly 669 under conditions of physical or emotional stress (Lonsdale, 1987a (Lonsdale, , 2006 . (Lonsdale, 688 1987a (Lonsdale, 688 , 1990 . contains high levels of thiamin relative to rodent requirements, the 695 typical human diet does not (Fleming et al., 2003 (Lonsdale, 2006) . 
